Table IV.
Bacterial and fungal infections amongst intensive care unit (ICU) patients at University Hospital Limerick (January–December 2021)
| COVID-19 ICU patients |
General ICU patients |
|||
|---|---|---|---|---|
| Tocilizumab | No tocilizumab | |||
| N | 41 | 33 | 332 | |
| Bacterial infection, % (N) | HAP | 59 (24) | 30 (10) | 8 (27) |
| BSI | 46 (19) | 27 (9) | 5 (17) | |
| CAUTI | 12 (5) | 12 (4) | 3 (9) | |
| Clostridioides difficile | 0 (0) | 3 (1) | 1 (3) | |
| SSTI | 2 (1) | 0 (0) | 0 (0) | |
| Fungal infection, % (N) | IFD | 10 (4) | 3 (1) | 1 (2) |
| Candidemia | 7 (3) | 0 (0) | 1 (3) | |
| Time to detection of first bacterial infection (days) | From hospital admission | |||
| Median | 14 | 22 | - | |
| Range | 3–102 | 3–94 | - | |
| From tozilizumab administration | ||||
| Median | 13 | - | - | |
| Range | 1–95 | - | - | |
COVID-19, coronavirus disease 2019; HAP, hospital-acquired pneumonia; BSI, bloodstream infection; CAUTI, catheter-associated urinary tract infection; SSTI, skin and soft tissue infection; IFD, invasive fungal disease.